Drug profile · INN
nusinersen sodium
SPINRAZA INITIAL APPROVAL
nusinersen sodium (SPINRAZA INITIAL APPROVAL) is a smn2 pre-mrna positive modulator. Route of administration: intrathecal. Current US regulatory status: approved.
Drug details — nusinersen sodium
- US status
- approved
- Class
- —
- Route
- INTRATHECAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
nusinersen sodium (SPINRAZA INITIAL APPROVAL) is a smn2 pre-mrna positive modulator. Route of administration: intrathecal. Current US regulatory status: approved.
Key facts
Mechanism of action
SMN2 pre-mRNA positive modulator
Primary target: SMN2 pre-mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nusinersen sodium?
nusinersen sodium (SPINRAZA INITIAL APPROVAL) is a smn2 pre-mrna positive modulator. Route of administration: intrathecal. Current US regulatory status: approved.
What is the brand name for nusinersen sodium?
SPINRAZA INITIAL APPROVAL is a marketed brand name for nusinersen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nusinersen sodium?
nusinersen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.